Ivabradine: beyond heart rate control.

Area of Science:

• Cardiology
• Pharmacology

Background:

• Chronic stable angina pectoris (CSAP) stems from coronary artery disease (CAD) where insufficient blood flow to the heart muscle causes ischemia.
• Elevated heart rate (HR) significantly contributes to myocardial ischemia and angina development.
• Beta-blockers and calcium channel blockers (CCBs) are standard treatments, but beta-blocker use is limited by contraindications and comorbidities.

Purpose of the Study:

• To review the use of ivabradine in treating CSAP.
• To explore ivabradine's potential in managing other cardiovascular conditions like cardiomyopathy and arrhythmias.

Main Methods:

• Review of randomized controlled trials on ivabradine in CSAP treatment.
• Analysis of ivabradine's mechanism of action as a selective heart rate-lowering agent.

Main Results:

• Ivabradine (5-10 mg twice daily) demonstrated anti-ischemic and anti-anginal effects comparable to beta-blockers and CCBs.
• Ivabradine has a favorable safety and tolerability profile.
• While not improving cardiac outcomes in all stable CAD patients, it may reduce CAD events in those with HR ≥ 70 bpm.

Conclusions:

• Ivabradine is a viable therapeutic option for CSAP, particularly when beta-blockers are contraindicated or poorly tolerated.
• Its HR-lowering effect suggests potential benefits in conditions like postural tachycardia syndrome and inappropriate sinus tachycardia.